acetylcysteine has been researched along with cefuroxime in 10 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 6 (60.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (20.00) | 29.6817 |
2010's | 1 (10.00) | 24.3611 |
2020's | 1 (10.00) | 2.80 |
Authors | Studies |
---|---|
Bonavita, E | 1 |
Mengoni, M; Testasecca, D | 1 |
Arsena, A; Ferrara, F; Giacobbe, G; Girbino, G | 1 |
Giannotti, G; Lombardo, S; Santangelo, G | 1 |
Dal Negro, RW; Pomari, C; Trevisan, F; Turco, P; Zoccatelli, O | 1 |
Andreoli, A; Baronio, L; Boner, AL; Valletta, EA; Vallone, G | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Benek, O; Benkova, M; Dolezal, R; Hepnarova, V; Hrabinova, M; Janockova, J; Jun, D; Kobrlova, T; Korabecny, J; Kucera, T; Mezeiova, E; Prchal, L; Sobolova, K; Soukup, O | 1 |
1 review(s) available for acetylcysteine and cefuroxime
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for acetylcysteine and cefuroxime
Article | Year |
---|---|
A combination of cefuroxime plus acetylcysteine in the intensive care of patients with respiratory insufficiency.
Topics: Acetylcysteine; Adolescent; Adult; Aged; Cefuroxime; Cephalosporins; Clinical Trials as Topic; Critical Care; Drug Combinations; Female; Humans; Male; Middle Aged; Respiratory Insufficiency; Time Factors | 1985 |
8 other study(ies) available for acetylcysteine and cefuroxime
Article | Year |
---|---|
Combined cefuroxime plus acetylcysteine in the treatment of bacterial infections of the respiratory tract.
Topics: Acetylcysteine; Adult; Aged; Bacterial Infections; Cefuroxime; Cephalosporins; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Respiratory Tract Infections | 1985 |
Physiopathological rationale and clinical aims of the use of a combination of cefuroxime and N-acetylcysteine in pneumology.
Topics: Acetylcysteine; Aged; Bronchi; Bronchial Diseases; Cefuroxime; Cephalosporins; Chronic Disease; Drug Therapy, Combination; Female; Humans; Lung Diseases, Obstructive; Male; Middle Aged | 1985 |
A combination of cefuroxime and N-acetyl-cysteine for the treatment of lower respiratory tract infections in children.
Topics: Acetylcysteine; Cefuroxime; Cephalosporins; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Infant; Male; Respiratory Tract Infections | 1985 |
Acute and exacerbated chronic respiratory tract infections: treatment with a combination of cefuroxime and acetylcysteine.
Topics: Acetylcysteine; Acute Disease; Adolescent; Adult; Aged; Cefuroxime; Cephalosporins; Chronic Disease; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Respiratory Tract Infections; Sputum | 1985 |
A combination of cefuroxime and N-acetyl-cysteine for the treatment of maxillary sinusitis in children with respiratory allergy.
Topics: Acetylcysteine; Adolescent; Asthma; Cefuroxime; Cephalosporins; Child; Chronic Disease; Drug Therapy, Combination; Humans; Maxillary Sinus; Respiratory Hypersensitivity; Sinusitis | 1984 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Discovery of novel berberine derivatives with balanced cholinesterase and prolyl oligopeptidase inhibition profile.
Topics: Berberine; Blood-Brain Barrier; Cell Line, Tumor; Cholinesterase Inhibitors; Cholinesterases; Drug Design; Humans; Prolyl Oligopeptidases | 2020 |